Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Travel Awards - Institute Community Support

University of Toronto

$3,700.00

Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario public drug benefit recipients

EF 2025-26

Résumé
Background: In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower-cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on eight innovator biologics to transition to biosimilars. Clinicians were reimbursed for supporting patients who transitioned. Objective: To evaluate the impact of this biosimilar switch policy on uptake and costs among public drug plan beneficiaries. Methods: We examined administrative data from April 2019 to June 2024. For the biologics (innovator and biosimilar) included in the policy, we reported the biosimilar market share, public drug program spending, and clinician support fees. We used time series analyses to evaluate the policy's impact, and forecasting to estimate drug cost savings. Results: From March 2023 to June 2024, the share of affected individuals on biosimilars increased from 21.7% to 96.5%. Drug cost savings were $65.2 million between April 2023 to June 2024, with most savings coming from non-insulin biosimilars. We estimated savings of $46.6 million in Year 1 (April 2023 to March 2024) and $95.9 million in Year 2 (April 2024 to March 2025). Clinician support fees totaled $3.4 million. Conclusions: Ontario's biosimilar policy achieved high biosimilar uptake and substantial cost savings. Future research should examine the impact of this policy on clinical outcomes to assess its broader implications for patient care and long-term sustainability.
Programme
Travel Awards - Institute Community Support
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
557823
Name
Ho Martin K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Travel Awards - Institute Community Support
Projecttitle
Measuring the impact of the substitution of innovator biologics with biosimilars on uptake and costs among Ontario public drug benefit recipients
Programtype2
Undefined
Orgnameinp2
University of Toronto
Cihramount2
$3,700
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Ics Travel Awards
Abstract
Background: In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower-cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on eight innovator biologics to transition to biosimilars. Clinicians were reimbursed for supporting patients who transitioned. Objective: To evaluate the impact of this biosimilar switch policy on uptake and costs among public drug plan beneficiaries. Methods: We examined administrative data from April 2019 to June 2024. For the biologics (innovator and biosimilar) included in the policy, we reported the biosimilar market share, public drug program spending, and clinician support fees. We used time series analyses to evaluate the policy's impact, and forecasting to estimate drug cost savings. Results: From March 2023 to June 2024, the share of affected individuals on biosimilars increased from 21.7% to 96.5%. Drug cost savings were $65.2 million between April 2023 to June 2024, with most savings coming from non-insulin biosimilars. We estimated savings of $46.6 million in Year 1 (April 2023 to March 2024) and $95.9 million in Year 2 (April 2024 to March 2025). Clinician support fees totaled $3.4 million. Conclusions: Ontario's biosimilar policy achieved high biosimilar uptake and substantial cost savings. Future research should examine the impact of this policy on clinical outcomes to assess its broader implications for patient care and long-term sustainability.
Competitiondate
202511
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ho, Martin K
Approvedterm
1 an 0 mois
Cihrcontribution2
MI #2~ $3,700~ $0~